The therapeutic mechanism of imatinib targeting tyrosine kinases

Imatinib (Imatinib), as a highly efficient targeted therapy drug, its unique mechanism of action lies in the precise inhibition of specific tyrosine kinases, especially the targeting effect on BCR-ABL fusion proteins and KITtyrosine kinases. In patients with chronic myelogenous leukemia (CML), 9 and 22 The translocation between chromosomes forms the "Philadelphia chromosome", which in turn produces the BCR-ABL fusion protein, which is an abnormally activated tyrosine kinase that can continuously stimulate intracellular signaling and promote the disordered proliferation of leukemia cells.

Imatinib binds closely to the active center of BCR-ABLtyrosine kinase, effectively blocking its kinase activity, thereby cutting off the transmission of downstream signaling pathways, inhibiting the proliferation of leukemia cells and promoting their apoptosis. This highly selective mechanism of action allows imatinib to target abnormal BCR-ABL proteins while minimizing its impact on normal cells, thus demonstrating excellent efficacy and low side effects.

In addition, imatinib also performs well in the treatment of gastrointestinal stromal tumors (GIST). GISTPatients' KITtyrosine kinase is often abnormally activated due to gene mutations, promoting the growth of tumor cells. Imatinib can effectively prevent the proliferation of tumor cells and promote their apoptosis by inhibiting the activity of KIT kinase, thereby achieving the purpose of treatment.

In summary, the precise targeted therapy mechanism of imatinib inhibits specific tyrosine kinases and blocks abnormal signaling of cancer cells to achieve the effect of inhibiting tumor growth and delaying the progression of the disease. Compared with traditional chemotherapy drugs, imatinib's targeted therapy is more precise and has fewer side effects, significantly improving patients' quality of life.